Follow Us
© 2026 Arizent. All rights reserved.
AI drug developer Recursion Pharmaceuticals is considering an Amazon Prime-style subscription model for selling its pipeline of medicines.
The Salt Lake City-based biotech wants to create a system where a U.S. employer could pay, for example, $45 a month per employee to access any medicine Recursion develops regardless of price — provided it’s prescribed by a doctor. If successful, the move has the potential to revolutionize how drugs are sold.
For reprint and licensing requests for this article, click here.
A financial spreadsheet alone cannot capture the total value and performance of a benefits program, nor can numbers on a ledger guarantee long-term operational success.
As GLP-1 spending climbs, employers are asking whether the drugs deliver enough value. Better data could help them measure the payoff more accurately.
With salary budgets holding steady and AI reshaping rewards, employers are looking to transparency, career growth and other benefits to retain top talent.
As the scope of gene therapy grows, understanding their impact and cost can help organizations decide how to cover them through their healthcare plans.
Brokers are urged to read the fine print on stop-loss contracts to ensure adequate coverage is in place, and have clients pool risk whenever necessary.
